文献速递头颈部肿瘤放疗姑息放疗与转移瘤

老年头颈部皮肤鳞状细胞癌原发与辅助放疗的价值

The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.
PubMed 文献 · Radiat Oncol · 2021-06-12

该回顾性单中心分析纳入69例2010至2019年间接受放疗的65岁以上头颈部皮肤鳞状细胞癌患者,中位年龄85岁。放疗方式包括原发(48%)、辅助(32%)和姑息(20%),2年局部区域控制率、无进展生存率和总生存率分别为54.2%、33.5%和40.7%。多因素分析显示阳性淋巴结状态是唯一显著恶化总生存的预后因素(HR 3.73,CI 1.54-9.03,p<0.01),急性和慢性毒性均很低。

要点

  • 老年头颈部cSCC患者放疗可行且耐受良好,仅4.3%出现急性3级毒性。
  • 阳性淋巴结状态是唯一显著恶化总生存的预后因素(HR 3.73)。
  • 2年局部区域控制率54.2%,轻度毒性可能允许适度剂量提升。

核心结论

  • 放疗在老年头颈部cSCC患者中可行且耐受良好,包括高龄患者。
  • 阳性淋巴结状态是唯一显著恶化总生存的预后因素。
  • 很轻的毒性可能允许适度剂量提升以改善局部区域控制。

研究设计与样本

  • 回顾性单中心分析,纳入2010至2019年间接受放疗的65岁以上头颈部cSCC患者69例,中位年龄85岁。

主要发现

  • 21.7%(15例)患者存在淋巴结病变,中位KPS 80%、CCI 6分。
  • 2年局部区域控制率、无进展生存率和总生存率分别为54.2%、33.5%和40.7%。
  • 65-80岁与80岁以上患者中位总生存分别为20个月和12个月(p<0.05)。
  • 多因素分析中阳性淋巴结状态是唯一显著恶化总生存的因素(HR 3.73,CI 1.54-9.03,p<0.01)。
  • 仅3例(4.3%)出现急性CTCAE 3级毒性,未观察到慢性CTCAE 2-5级毒性。

关键数值与推荐

  • 原发、辅助和姑息放疗的中位EQD2剂量分别为58.4 Gy、60 Gy和51.3 Gy。
  • 79.7%(55例)患者完成治疗并接受计划放疗剂量。

临床怎么用

  • 对老年头颈部cSCC患者可考虑放疗,包括原发、辅助和姑息情况。
  • 阳性淋巴结状态提示预后较差,需加强随访和关注。
  • 低毒性特征可能支持在合适患者中评估适度剂量提升以改善局部区域控制。

局限性

  • 回顾性单中心分析,样本量较小(69例)。
  • 未报告无进展生存率的具体数值(仅报告33.5)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine treatment patterns, oncological outcomes and toxicity rates in elderly patients receiving radiotherapy for cutaneous squamous cell carcinoma (cSCC) of the head-and-neck region. MATERIAL AND METHODS: In this retrospective single-center analysis, locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients > 65 years with cSCC of the head-and-neck region undergoing radiotherapy between 2010 and 2019 were calculated. The prognostic value of clinicopathological parameters on radiotherapy outcomes was analyzed using the Cox proportional hazards model. In addition, both acute and chronic toxicities were retrospectively quantified according to CTCAE version 5.0. RESULTS: A total of 69 elderly patients with cSCC of the head-and-neck region with a median age of 85 years were included in this analysis, of whom 21.7% (15 patients) presented with nodal disease. The majority of patients exhibited a good performance status, indicated by a median Karnofsky performance status (KPS) and Charlson Comorbidity Index (CCI) of 80% and 6 points, respectively. Radiotherapy was administered as primary (48%), adjuvant (32%) or palliative therapy (20%). 55 patients (79.7%) completed treatment and received the scheduled radiotherapy dose. Median EQD2 radiation doses were 58.4 Gy, 60 Gy and 51.3 Gy in the definitive, adjuvant and palliative situation, respectively. 2-year LRC, PFS and OS ranged at 54.2%, 33.5 and 40.7%, respectively. Survival differed significantly between age groups with a median OS of 20 vs. 12 months (p < 0.05) for patients aged 65-80 or above 80 years. In the multivariate analysis, positive lymph node status remained the only significant prognostic factor deteriorating OS (HR 3.73, CI 1.54-9.03, p < 0.01). Interestingly, neither KPS nor CCI impaired survival in this elderly patient cohort. Only 3 patients (4.3%) experienced acute CTCAE grade 3 toxicities, and no chronic CTCAE grade 2-5 toxicities were observed in our cohort. CONCLUSION: Radiotherapy was feasible and well-tolerated in this distinct population, showing the general feasibility of radiotherapy for cSCC of the head-and-neck region also in the older and oldest olds. The very mild toxicities may allow for moderate dose escalation to improve LRC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haehl E, Rühle A, Klink R, et al. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly. Radiat Oncol. 2021. PMID: 34118984. doi:10.1186/s13014-021-01832-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。